KYN-101|cas:2247950-73-6|西域试剂

KYN-101,98.17%

产品编号：Bellancom-134217| CAS NO：2247950-73-6| 分子式：C₂₂H₁₉FN₆| 分子量：386.42

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-134217	￥1800.00	杭州北京（现货）
Bellancom-134217	￥2800.00	杭州北京（现货）
Bellancom-134217	￥5200.00	杭州北京（现货）
Bellancom-134217	￥8000.00	杭州北京（现货）
Bellancom-134217	￥12000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

产品介绍

KYN-101 是一种有效的、选择性的和具有口服活性的 AHR 抑制剂。KYN-101 降低 CYP1A1 mRNA 表达。KYN-101 具有抗癌活性。

生物活性

KYN-101 is a potent, selective and orally active AHR inhibitor. KYN-101 decreases the CYP1A1 mRNA expression. KYN-101 shows anti-cancer activity.

体外研究

KYN-101 (0.5, 1 µM; 24 h) 降低 IDO^high 样本中的 CYP1A1 mRNA 表达。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

KYN-101 (10 mg/kg；口服；每日一次，持续 12 天) 在小鼠体内显示出抗癌活性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-8 weeks, C57BL/6J mice (B16IDO tumor-bearing mice)
Dosage:	10 mg/kg
Administration:	P.o.; daily for 12 days
Result:	Reduced tumor growth in B16IDO tumor-bearing mice and combination of KYN-101 and anti-PD-1 led to improved tumor growth delay and extended survival in CT26 models.

体内研究

KYN-101 (10 mg/kg；口服；每日一次，持续 12 天) 在小鼠体内显示出抗癌活性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-8 weeks, C57BL/6J mice (B16IDO tumor-bearing mice)
Dosage:	10 mg/kg
Administration:	P.o.; daily for 12 days
Result:	Reduced tumor growth in B16IDO tumor-bearing mice and combination of KYN-101 and anti-PD-1 led to improved tumor growth delay and extended survival in CT26 models.